Reinventing a $19.6 Billion Industry

100,000 knee replacements fail each year. We made a better solution. Now we’re pursuing a public listing.

Min. Investment

$500

Share Price

$10.01

Where We're Headed Next

More Live Demos

We're preparing a major live demonstration showcasing our active robotics' ability to advance the standard of orthopedic care. This is a unique opportunity for more investors to see our potential and join us.

Public Listing Path

We’re taking concrete steps towards a public listing. We have several hurdles to clear before we get there, but our funding could help us satisfy some exchange listing requirements.

Steadying the Ship

Inflation is rising, the Fed is hiking rates, and uncertainty around the economy is growing. By upping our capital when we have the chance can help us better navigate whatever comes our way.

How We're Deploying Our Capital

FDA submission is a long, expensive process and investors like you are helping us get there. Here’s how we’re using your investments.

Use of Proceeds

Use of Proceeds

Campaign marketing expenses or related reimbursement

Research and
development

% of Minimum
Proceeds Raised

Amount if
Minimum Raised

Use of Proceeds

Campaign marketing expenses or related reimbursement

Research and
development

% of Minimum
Proceeds Raised

Amount if
Minimum Raised

Use of Proceeds

Research and
development

Campaign marketing expenses or related reimbursement

% of Minimum
Proceeds Raised

Amount if
Minimum Raised

% of Minimum
Proceeds Raised

Amount if
Minimum Raised

Campaign marketing expenses or related reimbursement

Research and development

$19.6B

Joint Replacement Market

Over 1M

Annual knee replacements in US

250%

Projected procedure growth by 2030

Under 65-year-olds are the fastest-growing demographic

Patients under 65 years are the fastest-growing population of TKR recipients, expected to account for more than 50% of knee replacement procedures by the year 2030

Market is ripe for disruption

Four companies currently dominate the multi-billion dollar joint reconstruction market with an 82% combined share in knee replacement. Monogram is building critical infrastructure to scale growth. We have signed deals with 2 distributors and have more on the way.

01

Building Critical Infrastructure to
Scale Growth

The Monogram Knee System Won FDA Approval

We have licensed, FDA-approved, clinically well-established implant components that will be integrated into our proprietary Monogram knee system. Monogram is leveraging the testing and proven performance of these components (articulation, locking mechanisms, inserts) to focus on our novel tibial component and robotics

As Seen In

"Given the sheer number of knee and hip replacement procedures every year, the fact that joint reconstruction technology has remained unchanged for over 50 years is perplexing."

"Monogram has a first-to-market advantage in a sector that's about to get even more competitive."

"Monogram Orthopedics is ushering in personalized orthopedic care by combining proprietary 3D printing technology with next-generation navigated surgical robotics".

"Monogram is developing a better way by commercializing highly personalized joint implants unique to every patient and a first-of-its-kind active robotics system that performs precise bone cuts."

"Monogram has conducted studies with UCLA and demonstrated Monogram process was about seven times more stable than current hip replacement techniques."

National Science Foundation
03

50% of early revision surgeries after a knee replacement are related to instability, malalignment or malposition, and failure of fixation.

Knees

Rate of re-admission:

7%-8%.

Approximately 50%-75% are surgical.

36%

Survey: 36% of TKA patients would not have undergone the surgery knowing what it did for them (10 years later).

1 in 5

1 in 5 patients are not satisfied with the results of their total knee replacement.

Potentially Preventable Reasons for revision Procedure
Mechanical Loosening
19%
Other Mechanical Problems
10%
Dislocation / instability
7%
Other mechanical complications
5%

By 2027, approximately 50% of all knee procedures will be robotic, up from 11% in 2019.

Significant Increases

in robotic adoption are expected over the next 5-10 years.
At least 50% of procedures will be robotic by 2027
Estimates for procedure volumes vary but TKA projections are generally between 935,000 and 1,260,000 by 2030

Stryker (Mako) is the only navigated robot arm on the market with a cutting end-effector. Monogram believes we will be the first active navigated arm on the market.

Robotic Surgical Assistants

Monogram’s navigated surgical robot features several enhancements that will improve surgical experiences including:

Closed Loop Tracking

For safety Monogram has implemented a "closed-loop" system. The real-time position of the cutting system is tracked at all times.

Increased Range of Motion

Seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage the kinematic redundancy to avoid interoperative boundaries and optimize execution.

Active Navigated Milling

High-efficiency rotary cutting system to gently excavate the negative space for the patient-optimized implant.
Keep on Moving.

Our custom-fitted implants will help patients enjoy their lives to the fullest.

Thank you! Your submission has been received.
Oops! Something went wrong while submitting the form.
Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software
1.Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software

The Business Model

We believe that precision implants with precision insertion are the future of orthopaedics. Monograms principal competitive advantage will be our ability to produce customized, robotically inserted orthopaedic implants rapidly and at scale. The product solution architecture we are developing enables rapid fabrication and mass personalization of robotically inserted, patient specific orthopaedic implants.

Company Highlights

Generated Revenue

Implant sales in 2021 with 2 active distributors

NSF Grant

Winner of prestigious award from National Science Foundation (NSF)

Cadaver Lab

350 sq. ft. cadaver lab complete

14 Patents

14 Patent applications filed

$26M

Have already raised $26M

The Technology Platform

Monogram Orthopaedics is developing a product solution architecture to enable mass personalization by linking 3D printing and robotics via automated digital image analysis algorithms.

The Robotics

Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy execution. The robot will also utilize complex tracking capabilities for gentle navigation.

Our Implants

Monogram’s components are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific solution to address the primary shortcomings of their generic counterparts.

The Technology Platform

Monogram Orthopaedics is developing a product solution architecture to enable mass personalization by linking 3D printing and robotics via automated digital image analysis algorithms.

The Robotics

Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy execution. The robot will also utilize complex tracking capabilities for gentle navigation.

Our Implants

Monogram’s components are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific solution to address the primary shortcomings of their generic counterparts.

Meet the Team

See Our Team

Douglas Unis, Md

Founder & Chief Medical Officer

Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.

Benjamin Sexson - CEO

CFA, Chief Executive Officer

Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.

Paul Riss

CPA, MBA, INTERIM CFO

Experienced executive with a demonstrated history of completing SEC filings, focusing on the Securities Exchange Act of 1934 and Section 4(a)(6) of the Securities Act of 1933.  Currently serves as a Director for NetCapital and was a CPA with Ernst & Young.

Kamran Shamaei, P.hD.

CTO

Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots.

Christopher Scifert, P.hD.

Director of Product Development Implants and Instruments

Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Kevin Posey

DIRECTOR OF QUALITY AND REGULATORY ASSURANCE

Muhammad Afnan

Director of Software Engineering

Sophia Sangiorgio, PhD

Director, Orthopaedic Institute for Children

Laura Gilmour

Global Medical B. Development Manager at EOS NA

Matt DiCicco, M.S.

Robotics, MIT

Dr. Roshan Shah

Director of Complex Adult Hip and Knee Reconstruction at Columbia University

Robert Jamieson

Board Certified Orthopaedic Surgeon at The Orthopedic Specialty Center of Northern California

Dr. Matthew E. Heinrich

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

Darwin Chen

Associate Professor of Orthopaedics at Icahn School of Medicine at Mt Sinai

Dr. Gregory Catlett

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

Business Updates

Monogram Wins Prestigious Award from National Science Foundation
1/5/2022

Monogram is pleased to announce that it has received an award notice from The National Science Foundation (NSF) for its application "Development of a tracking system for computer-assisted surgery." The SBIR Phase I award will support the research of a novel Monogram tracking system designed to mitigate the occlusion limitations of conventional line-of-sight systems while reducing the OR footprint, lowering capital cost, and minimizing patient trauma associated with secondary incisions. Monogram has filed for patent protection for these novel concepts.

"It is an incredible honor to be chosen for such a prestigious award," said CEO Ben Sexson. "It's a significant endorsement that speaks to the caliber of our team and ideas as well as the tremendous efforts our company is making to further the field of orthopedic medicine. We are especially thankful to Northern Digital for their support with this application.

"The NSF follows a rigorous review process, approving a small number of the full proposals. Per the NSF's Program Solicitation document, "the SBIR/STTR Phase I Programs are highly competitive. While success rates vary year-to-year, approximately 10-15% of the full proposals submitted are selected for an award. Thus, there are many qualified businesses applying to the program each year that do not receive funding." The Small Business Innovation Research Program awards such grants in phases. The Phase I award of $256,000 will help support proof of concept refinement. Monogram intends to file for a more significant Phase II award pending successful completion of Phase I activities. Funding rates for Phase II applications tend to be higher. Once a small business is awarded a Phase I SBIR/STTR grant (up to $256,000), it becomes eligible to apply for a Phase II (up to $1,000,000). Small businesses with Phase II funding are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.

"Operating rooms can get very crowded, and the footprints are often not conducive for conventional tracking methods," said CMO Dr. Doug Unis. "And while navigation offers considerable clinical benefits, secondary incisions and similar considerations are not ideal for patients. To receive recognition from such a prestigious organization for our efforts to advance the current state-of-the-art in surgical robotics is a tremendous achievement."

The National Science Foundation (NSF) is an independent agency of the United States government that supports fundamental research and education in all the non-medical fields of science and engineering.

Keep following for more updates on how Monogram uses high precision, patient-specific implants with state-of-the-art robotics to improve patient outcomes.

Monogram Starts Generating Revenue with First TKA Procedure
about 2 months ago

Monogram is pleased to announce that on Monday, March 22nd, 2021, we completed our first Total Knee Arthroplasty ("TKA") procedure as a company and will now be generating revenue. Facilitating the requirements needed to perform our first case is a significant accomplishment for Monogram and the culmination of a tremendous team effort.  

Monogram is now:

  • HIPAA compliant
  • has implemented an ERP system with lot tracing
  • has secured implant component supply
  • has established distribution relationships
  • has implemented several critical insurance policies
  • has run its first cadaver lab in its Austin facility

"Our philosophy has always been to build an operating business as quickly as possible, which means much more than having competitive products," said CEO Ben Sexson. "The basic infrastructure and systems required to support and scale growth in our highly regulated market are demanding and cannot be overlooked. Pulling all the pieces together to facilitate sales in such a highly regulated market is a major first step towards our goal of building a real orthopedic company.  We believe the first dollars of revenue are always the hardest."

Monogram has not provided sales guidance but would like the investors to calibrate expectations appropriately. "Aggressively driving sales requires a significant working capital investment, and the most compelling components of our product pipeline remain in development and our focus," said CEO Ben Sexson. "We want to build a company that can scale at the appropriate time. The goal right now is forward-thinking, and we are focused on the long-term.  In the long-term, innovative products that improve patient lives are what matter to us most."


Monogram expects to continue generating revenues and remains optimistic about its ongoing growth prospects.


Monogram Executes Strategic License of Unicondylar Knee Replacement Implant
3 months ago

Monogram is pleased to announce it has successfully executed a license agreement for an FDA-approved Unicondylar Knee Arthroplasty ("UKA") implant design from an established orthopedic manufacturer. Monogram intends to prioritize the launch of total knee and partial knee robotic applications.    

"The orthopedic market today is too siloed. Knee teams optimize knee products. Hip teams optimize hip products. Spine products are a completely different focus altogether. After the fact, large organizations try to force-fit platform technologies into these siloes," said CEO Ben Sexson. "Elon Musk explains this organization problem perfectly here. Monogram is building an orthopedic platform technology. We believe an orthopedic robot capable of addressing multiple clinical applications with a single-arm simplifies the capital equipment sales process with hospitals and will be massively differentiated. Integrating partial knees and other products into our robotic platform is critical for this."

Monogram's strategy is to develop a single, highly robust robotic platform technology that can address clinical opportunities across significant orthopedic applications, for example, knees (both total and partial), hips, shoulders, ankles, and spine. Monogram expects to begin developing its partial knee application when it enters V&V testing on its total knee application.

"If you look at Mako and their success, they started with partial knees, and after Stryker acquired them, they launched the total knee application in 2015," said Chief Medical Officer Dr. Doug Unis. "To compete with Mako, at a minimum, we will need robotic prep for both a total knee and a partial knee. Longer-term, we plan on addressing hips and other markets."

Monogram to Present at OTC Markets Regulation A+ Investor Conference - Register now!
4 months ago

Monogram will be speaking Thursday, February 11, 2021, @ 11:30 AM ET at the OTC Markets Regulation A+ Investor Conference.  The presentation is 30 minutes and will include a management Q&A.

Here is the registration link here

Monogram Executes First Hospital Contract: Expect Revenues as early as First Quarter 2021
4 months ago

Monogram is pleased to announce that it has executed a Product Purchase Agreement with its first significant hospital institution.  The company expects it could begin placing implants in patients and generating revenue as early as the first quarter of 2021 (although cautions that Covid-19 and unforeseen market factors could impact timing).    

"Being accepted by the value analysis committee of a major hospital institution is a significant milestone for our company," said CEO Ben Sexson.  "We expect to begin generating revenues very soon.  We continue to execute on our strategic initiatives, and we are extremely pleased with the progress of our product pipeline and our pace of growth.  Our goal is to become a competitor in the ortho space as quickly as possible."


Monogram management looks forward to sharing our continued progress and is thankful for our shareholders without whom this progress would not have been possible.

FAQs

 Why invest in startups?
Crowdfunding allows investors to support startups and early-growth companies that they are passionate about. This is different from helping a company raise money on Kickstarter. With Regulation CF Offerings, you aren’t buying products or merchandise. You are buying a piece of a company and helping it grow.
How much can I invest?
Investors other than accredited investors are limited in the amounts they are allowed to invest in all Regulation Crowdfunding offerings (on this site and elsewhere) over the course of a 12-month period: If either of an investor’s annual income or net worth is less than $107,000, then the investor’s investment limit is $2,200, or 5 percent of the greater of the investor’s annual income or net worth, whichever is greater. If both an investor’s annual income and net worth are $107,000 or higher, then the investor’s limit is 10 percent of the greater of their annual income or net worth, or $107,000 whichever is greater. Accredited investors are not limited in the amount they can invest.
How do I calculate my net worth?
Calculating net worth involves adding up all your assets and subtracting all your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
What do I need to know about early-stage investing? Are these investments risky?
Investing in startups and small businesses is inherently risky and standard company risk factors such as execution and strategy risk are often magnified at the early stages of a company. In the event that a company goes out of business, your ownership interest could lose all value. Furthermore, private investments in startup companies are illiquid instruments that typically take up to five and seven years (if ever) before an exit via acquisition, IPO, etc.
When will I get my investment back?
Monogram Orthopaedics Inc.. is a privately held company, and its shares are not traded on a public stock exchange. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically receive a return on your investment under the following two scenarios: The company gets acquired by another company. The company goes public (makes an initial public offering on the NASDAQ, NYSE, or another exchange). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on the exchange. It can take 5-7 years (or longer) to see a distribution or trading, as it takes years to build companies. In many cases, there will not be any return as a result of business failure. Investments in private placements and start-up investments in particular are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments tend to be in earlier stages of development, and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors on Regulation CF offerings will receive securities that are subject to holding period requirements. The most sensible investment strategy for start-up investing may include a balanced portfolio of different start-ups. Start-ups should only be part of your overall investment portfolio. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.
Can I sell my shares?
Shares sold via Regulation Crowdfunding offerings have a one-year lock up period before those shares can be sold under certain conditions.
Exceptions to limitations on selling shares during the one-year lock up are transfers:
- to the company that issued the securities; - to an accredited investor; - to a family member (defined as a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships.); - in connection with your death or divorce or other similar circumstance;
What happens if a company does not reach their funding goal?
If a company does not reach their minimum funding goal, all funds will be returned to the investors after the closing of their offering.
How can I learn more about a company's offering?
All available financial information can be found on the offering pages for the company’s Regulation Crowdfunding offering.
What if I change my mind about investing?
You may cancel your investment at any time, for any reason until 48 hours prior to a closing occurring. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email info@monogramorthopedics.com.

Join the Discussion

Loading Comments